Long COVID: major findings, mechanisms and recommendations

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(3), P. 133 - 146

Published: Jan. 13, 2023

Language: Английский

---

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Journal of Hypertension, Journal Year: 2023, Volume and Issue: 41(12), P. 1874 - 2071

Published: June 24, 2023

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).

Language: Английский

---

Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review

The Journal of Infectious Diseases, Journal Year: 2022, Volume and Issue: 226(9), P. 1593 - 1607

Published: April 14, 2022

Abstract Background This study aims to examine the worldwide prevalence of post-coronavirus disease 2019 (COVID-19) condition, through a systematic review and meta-analysis. Methods PubMed, Embase, iSearch were searched on July 5, 2021 with verification extending March 13, 2022. Using random-effects framework DerSimonian-Laird estimator, we meta-analyzed post-COVID-19 condition at 28+ days from infection. Results Fifty studies included, 41 meta-analyzed. Global estimated pooled was 0.43 (95% confidence interval [CI], .39–.46). Hospitalized nonhospitalized patients had estimates 0.54 CI, .44–.63) 0.34 .25–.46), respectively. Regional Asia (0.51; 95% .37–.65), Europe (0.44; .32–.56), United States America (0.31; .21–.43). for 30, 60, 90, 120 after infection be 0.37 .26–.49), 0.25 .15–.38), 0.32 .14–.57), 0.49 .40–.59), Fatigue most common symptom reported 0.23 .17–.30), followed by memory problems (0.14; .10–.19). Conclusions finds is substantial; health effects COVID-19 seem prolonged can exert stress healthcare system.

Language: Английский

---

Long COVID after breakthrough SARS-CoV-2 infection

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(7), P. 1461 - 1467

Published: May 25, 2022

Abstract The post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection—also referred to as Long COVID—have been described, but whether breakthrough SARS-CoV-2 infection (BTI) in vaccinated people results is not clear. In this study, we used the US Department Veterans Affairs national healthcare databases build a cohort 33,940 individuals with BTI and several controls without evidence infection, including contemporary ( n = 4,983,491), historical 5,785,273) 2,566,369) controls. At 6 months after show that, beyond first 30 days illness, compared controls, exhibited higher risk death (hazard ratio (HR) 1.75, 95% confidence interval (CI): 1.59, 1.93) incident (HR 1.50, CI: 1.46, 1.54), cardiovascular, coagulation hematologic, gastrointestinal, kidney, mental health, metabolic, musculoskeletal neurologic disorders. were consistent comparisons versus Compared who previously 113,474), lower risks 0.66, 0.58, 0.74) 0.85, 0.82, 0.89). Altogether, findings suggest that vaccination before confers only partial protection phase disease; hence, reliance on it sole mitigation strategy may optimally reduce long-term health consequences infection. emphasize need for continued optimization strategies primary prevention will guide development care pathways BTI.

Language: Английский

---

Atherosclerosis: Recent developments

Cell, Journal Year: 2022, Volume and Issue: 185(10), P. 1630 - 1645

Published: May 1, 2022

Atherosclerosis is an inflammatory disease of the large arteries that major cause cardiovascular (CVD) and stroke. Here, we review current understanding molecular, cellular, genetic, environmental contributions to atherosclerosis, from both individual pathway systems perspectives. We place emphasis on recent developments, some which have yielded unexpected biology, including previously unknown heterogeneity smooth muscle cells in atherosclerotic lesions, roles for senescence clonal hematopoiesis, links gut microbiome.

Language: Английский

---

Risks and burdens of incident diabetes in long COVID: a cohort study

The Lancet Diabetes & Endocrinology, Journal Year: 2022, Volume and Issue: 10(5), P. 311 - 321

Published: March 21, 2022

Language: Английский

---

Distinguishing features of long COVID identified through immune profiling

Nature, Journal Year: 2023, Volume and Issue: 623(7985), P. 139 - 148

Published: Sept. 25, 2023

Abstract Post-acute infection syndromes may develop after acute viral disease 1 . Infection with SARS-CoV-2 can result in the development of a post-acute syndrome known as long COVID. Individuals COVID frequently report unremitting fatigue, post-exertional malaise, and variety cognitive autonomic dysfunctions 2–4 However, biological processes that are associated persistence these symptoms unclear. Here 275 individuals or without were enrolled cross-sectional study included multidimensional immune phenotyping unbiased machine learning methods to identify features Marked differences noted circulating myeloid lymphocyte populations relative matched controls, well evidence exaggerated humoral responses directed against among participants Furthermore, higher antibody non-SARS-CoV-2 pathogens observed COVID, particularly Epstein–Barr virus. Levels soluble mediators hormones varied groups, cortisol levels being lower Integration data into models identified key most strongly status. Collectively, findings help guide future studies pathobiology developing relevant biomarkers.

Language: Английский

---

Acute and postacute sequelae associated with SARS-CoV-2 reinfection

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2398 - 2405

Published: Nov. 1, 2022

Abstract First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated increased risk of and postacute death sequelae in various organ systems. Whether reinfection adds to risks incurred after first unclear. Here we used the US Department Veterans Affairs’ national healthcare database build a cohort individuals one SARS-CoV-2 ( n = 443,588), (two or more infections, 40,947) noninfected control 5,334,729). We inverse probability-weighted survival models estimate 6-month burdens death, hospitalization incident sequelae. Compared no reinfection, contributed additional (hazard ratio (HR) 2.17, 95% confidence intervals (CI) 1.93–2.45), (HR 3.32, CI 3.13–3.51) including pulmonary, cardiovascular, hematological, diabetes, gastrointestinal, kidney, mental health, musculoskeletal neurological disorders. The were evident regardless vaccination status. most pronounced phase but persisted at 6 months. controls, cumulative repeat according number infections. Limitations included mostly white males. evidence shows that further increases multiple systems phase. Reducing overall burden disease due will require strategies for prevention.

Language: Английский

---

Long-term neurologic outcomes of COVID-19

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2406 - 2415

Published: Sept. 22, 2022

Abstract The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation postacute sequelae at 1 year has not been undertaken. Here we use the national healthcare databases US Department Veterans Affairs to build cohort 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls; inverse probability weighting balance cohorts, estimate risks burdens incident disorders 12 months following SARS-CoV-2 infection. Our results show that in phase there was increased risk an array including ischemic hemorrhagic stroke, cognition memory disorders, peripheral nervous system episodic (for example, migraine seizures), extrapyramidal movement mental health musculoskeletal sensory Guillain–Barré syndrome, encephalitis or encephalopathy. We estimated hazard ratio any sequela 1.42 (95% confidence intervals 1.38, 1.47) burden 70.69 63.54, 78.01) per 1,000 persons months. were elevated even people who did require hospitalization during COVID-19. Limitations include comprising mostly White males. Taken together, our provide evidence long-term had

Language: Английский

---

Risks of mental health outcomes in people with covid-19: cohort study

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e068993 - e068993

Published: Feb. 16, 2022

To estimate the risks of incident mental health disorders in survivors acute phase covid-19.Cohort study.US Department Veterans Affairs.Cohort comprising 153 848 people who survived first 30 days SARS-CoV-2 infection, and two control groups: a contemporary group (n=5 637 840) with no evidence SARS-CoV-2, historical 859 251) that predated covid-19 pandemic.Risks prespecified outcomes, calculated as hazard ratio absolute risk difference per 1000 at one year, corresponding 95% confidence intervals. Predefined covariates algorithmically selected high dimensional were used to balance groups through inverse weighting.The showed an increased anxiety (hazard 1.35 (95% interval 1.30 1.39); 11.06 9.64 12.53) year), depressive (1.39 (1.34 1.43); 15.12 (13.38 16.91) stress adjustment (1.38 13.29 (11.71 14.92) use antidepressants (1.55 (1.50 1.60); 21.59 (19.63 23.60) year) benzodiazepines (1.65 (1.58 1.72); 10.46 (9.37 11.61) year). The opioid prescriptions also (1.76 (1.71 1.81); 35.90 (33.61 38.25) (1.21 1.48); 0.96 (0.59 1.37) other (non-opioid) substance (1.20 (1.15 1.26); 4.34 (3.22 5.51) neurocognitive decline (1.80 (1.72 1.89); 10.75 (9.65 11.91) sleep (1.41 1.45); 23.80 (21.65 26.00) any diagnosis or prescription was (1.60 1.66); 64.38 (58.90 70.01) examined outcomes even among not admitted hospital highest those during covid-19. Results consistent group. consistently higher comparisons versus for seasonal influenza, cause.The findings suggest survive are array disorders. Tackling should be priority.

Language: Английский

---